Cost-utility of surgical sutureless bioprostheses vs TAVI in aortic valve replacement for patients at intermediate and high surgical risk

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, November 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#23 of 525)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 9 news outlets

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 32 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 9 news stories from 9 outlets.

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

PharmiWeb, 17 Jan 2019

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the publication of three separate…

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

Business Journals, 17 Jan 2019

Recently published data reinforces the ability of Perceval to optimize the surgical approach to aortic valve replacement LONDON-…

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve?s Strong Performance and Economic Advantage in Aortic Disease Treatment

Ariva, 17 Jan 2019

LONDON --(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the…

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment - Press Release

Digital Journal, 17 Jan 2019

LONDON--(Business Wire)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the…

News story from Finanz Nachrichten on Thursday 17 January 2019

Finanz Nachrichten, 17 Jan 2019

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

Business Wire, 17 Jan 2019

Recently published data reinforces the ability of Perceval to optimize the surgical approach to aortic valve replacement LONDON-…

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valves Strong Performance and Economic Advantage in Aortic Disease Treatment

Bioportfolio, 17 Jan 2019

Recently published data reinforces the ability of Perceval to optimize the surgical approach to aortic valve replacement…

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

NASDAQ, 17 Jan 2019

@media screen and (max-device-width: 480px){body{ font-size:30pt !important;}}.bwalignc {text-align: center}.bwlistitemmargb {mar…

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

Biospace, 17 Jan 2019

Jan. 17, 2019 14:00 UTC Recently published data reinforces the ability of Perceval to optimize the surgical approach to aortic…

Dove Medical Press

Article Metrics

Cost-utility of surgical sutureless bioprostheses vs TAVI in aortic valve replacement for patients at intermediate and high surgical risk

About this Attention Score

Mentioned by

Citations

Readers on

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

PharmiWeb, 17 Jan 2019

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

Business Journals, 17 Jan 2019

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve?s Strong Performance and Economic Advantage in Aortic Disease Treatment

Ariva, 17 Jan 2019

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment - Press Release

Digital Journal, 17 Jan 2019

News story from Finanz Nachrichten on Thursday 17 January 2019

Finanz Nachrichten, 17 Jan 2019

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

Business Wire, 17 Jan 2019

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valves Strong Performance and Economic Advantage in Aortic Disease Treatment

Bioportfolio, 17 Jan 2019

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

NASDAQ, 17 Jan 2019

New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment

Biospace, 17 Jan 2019